Zollinger-Ellison syndrome (ZE syndrome) is a rare endocrine disorder characterized by excessive secretion of gastrin, a hormone responsible for stimulating the production of gastric acid. This pathology is usually associated with the presence of tumors called gastrinomas, which are most often localized in the pancreas or duodenum. Hospitalization of patients is often due to serious complications, such as duodenal ulcers and chronic gastritis, leading to the development of gastroesophageal reflux disease and osteoporosis. This condition requires a comprehensive approach to diagnosis and treatment, since advanced forms can lead to serious disability and a decrease in the quality of life of patients.
History of the disease and interesting historical facts
Zollinger-Ellison syndrome was first described in the early 20th century, but it was the work of gastroenterologists in 1955 that attracted significant attention to the disease, when doctors with two surnames, William Zollinger and Edward Ellison, presented clinical cases of patients with similar symptoms. These researchers were able to demonstrate that gastrinomas not only contribute to increased secretion of gastric acid, but also affect the development of peptic ulcer disease. In the following decades, scientists continued to study the mechanisms and pathogenesis of this syndrome, including the genetic and molecular basis of its pathology.
Epidemiology
Zollinger-Ellison syndrome is a relatively rare disease. According to epidemiological studies, its prevalence is approximately 0.5–2 cases per 1 million population per year. Most often, the syndrome is detected in people aged 30 to 60 years, with men suffering from this disease somewhat more often than women. In most cases, gastrinomas are malignant, and according to studies, only about 50% of detected gastrinomas are benign. This emphasizes the importance of early diagnosis and proper assessment of the clinical situation to prevent potential complications.
Genetic predisposition to this disease
Genetic predisposition to Zollinger-Ellison syndrome is strongly associated with inherited syndromes such as multiple endocrine neoplasia type II (MEN II). The main gene involved is RET (REarranged during Transfection), mutations of which play a central role in the development of this syndrome. In patients with MEN II, gastrin levels may be elevated as a result of the presence of gastrinomas that arise in the context of various tumors, including pheochromocytomas and medullary thyroid carcinomas. Other genes that interact with RET are also highly expressed, providing additional mechanisms for the development of gastrinomas and increased gastrin secretion.
Risk factors for the development of this disease
Zollinger-Ellison syndrome can occur under the influence of various risk factors, among which are:
- Hereditary factors (presence of syndromes such as MEN II)
- Age (often occurs in middle-aged people)
- Gender (higher chances for men)
- Chronic diseases of the gastrointestinal tract (peptic ulcer, gastritis)
- Professional factors (exposure to carcinogens)
These factors can not only contribute to the development of the disease, but also aggravate its course and clinical manifestations.
Diagnosis of this disease
Zollinger-Ellison syndrome diagnostics includes several methods that allow the diagnosis to be established and the patient's condition to be assessed. The main symptoms of the disease include:
- Acute or chronic abdominal pain
- Heartburn and Gastroesophageal Reflux Disease
- Persistent duodenal ulcers
- Diarrhea
Laboratory studies typically include serum gastrin levels, which are significantly elevated. Radiologic studies may include ultrasound, CT, or MRI of the abdomen to detect gastrinomas. In some cases, endoscopic procedures may be necessary to visualize and biopsy suspected lesions. Differential diagnosis includes separating gastrinoma from other diseases such as peptic ulcer and other neonatal processes in the gastrointestinal tract.
Treatment
Treatment of Zollinger-Ellison syndrome requires an individual approach and may include both pharmacological and surgical interventions.
- General treatment is aimed at controlling symptoms and preventing complications.
- Pharmacological treatment is based on the use of proton pump inhibitors (PPIs), such as omeprazole, lansoprazole
- Surgical treatment may include resection of the gastrinoma if there is a localized mass.
- Use of chemotherapy or targeted therapy in metastatic forms
Thus, the choice of treatment methods depends on the stage of the disease, the level of aggressiveness of the tumor and the general condition of the patient.
List of medications used to treat this disease
Medicines used to treat Zollinger-Ellison syndrome include:
- Omeprazole
- Lansoprazole
- Pantoprazole
- Rabeprazole
- Somatostatin and its analogues (eg, octreotide)
These drugs are designed to control the secretion of gastric acid and relieve symptoms associated with increased secretion of gastrin.
Disease monitoring
Monitoring Zollinger-Ellison syndrome is important to assess the effectiveness of treatment and identify potential complications. Monitoring steps include recording gastrin levels, performing regular imaging studies to track changes in the size of gastrinomas, and detecting metastases. The prognosis for patients with Zollinger-Ellison syndrome varies depending on the nature of the tumor, its size, and its grade. Complications that arise from the disease may include:
- Perforation of ulcers
- Bleeding
- Acute attacks of pancreatitis
- Malabsorption syndrome
Age-related features of the disease
Zollinger-Ellison syndrome has age-related features. In children and adolescents, the disease is extremely rare and is most often associated with hereditary syndromes. In middle-aged patients, the disease may progress slowly, but the risk of complications increases with age. In elderly patients, insufficient recognition of symptoms may lead to a delay in diagnosis, which makes this group more vulnerable to serious pathologies associated with gastritis and ulcers.
Questions and Answers
- What is Zollinger-Ellison syndrome? Zollinger-Ellison syndrome is a rare disorder characterized by excess secretion of gastrin, often caused by gastrinomas, leading to increased production of stomach acid and ulceration.
- How is Zollinger-Ellison syndrome diagnosed? Diagnostics includes determination of gastrin levels in the blood, imaging studies (ultrasound, CT, MRI) and endoscopic studies.
- What medications are used to treat the syndrome? Proton pump inhibitors (omeprazole, lansoprazole) and a somatostatin analogue (octreotide) are used for treatment.
- What is the probability of malignant transformation of gastrinomas? According to statistics, about 50% gastrinomas are malignant, so early diagnosis and monitoring of the condition is important.
- What complications can Zollinger-Ellison syndrome lead to? Possible complications include ulcer perforation and gastrointestinal bleeding, which require emergency medical attention.
